New Zealand’s Pharmaceutical
Management Agency (PHARMAC)
has announced the ‘go live’ of its
new Exceptional Circumstances
Framework, the system designed
to provide medication and medical
devices outside the normal
framework of the Pharmaceutical
Schedule funding process.
The system enables prescribers
to use a treatment which is not
on the official Pharmaceutical
Schedule, with unlisted treatments
for particular patients able to be
applied for using the Named Patient
Pharmaceutical Assessment process.
Applications will be assessed
against nine formal “decision
criteria” which explicitly exclude
non-clinical circumstances, patient
preference and clinical benefits
experienced in a funded trial.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Sep 15
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.